RESI Shanghai Innovation Challenge


9:00 AM Therapeutics

10:00 AM Therapeutics & Diagnostics

11:00 AM Medical Devices

1:00 PM Medical Devices

2:00 PM Therapeutics

3:00 PM Therapeutics

RESI Taipei Innovation Challenge


9:00 AM Medical Devices

10:00 AM Mix of Therapeutics, Diagnostics, Digital Health

11:00 AM Therapeutics

1:00 PM Mix of Therapeutics, Diagnostics, Digital Health

2:00 PM Medical Devices & Diagnostics

3:00 PM Therapeutics & Digital Health

RESI Shanghai Innovation Challenge Sponsored by VIVA Biotech

LSN invites all global early-stage companies across Biotech, Medtech, Diagnostics & Digital Health to apply for the RESI Innovation Challenge. If you are a scientist-entrepreneur or fundraising CEO starting to accumulate compelling proof-of-concept animal data or early stage clinical data, the RESI Innovation Challenge is for you. The 30 most innovative applicants will be hand selected by Life Science Nation’s internal scientific review board to be part of the RESI Innovation Challenge, presenting their technologies in an exhibition-style format throughout the full-day conference. Presenters will gain additional exposure to investors and potential partners by showcasing their companies and products in a poster format. Unlike traditional 5- to 15-minute pitch presentations that do not allow any real interaction and provide no actionable feedback from investors, the RESI Innovation Challenge enables executives to pitch directly to attendees, generating more in-depth conversations with more investors, more frequently throughout the event.

The RESI Pitch Challenge is for the earliest stage companies associated with tech hubs-incubators, accelerators, tech transfer offices, universities, hospitals and research labs. The companies selected will have the opportunity to pitch to a panel of investors at RESI. 

Apply to RESI Innovation Challenge

To add some friendly competition to the mix, the RESI Innovation Challenge invites all attendees to participate in a virtual investment contest. At the start of the day, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 23,000 newsletter readership. Whether you are an investor, an entrepreneur, or a service provider, make sure you check out the exhibit hall to meet with some of the top innovators in the field and invest your “RESI Cash.” We will see you there!

RESI Boston 2019 Innovation Challenge Winners


First Place: Zepto Life Technologies

Zepto, an in-vitro diagnostics company, features uniquely-accurate and multiplex-ready “lab-on-a-chip” technology – co-developed with the Mayo Clinic – to improve patient outcomes through superior assay performance at patients’ exact points of need (a $12B market). Zepto’s fully-automated lab-on-a-chip Immunoassay Platform can conveniently deliver “central lab-quality” performance almost anywhere. Initially, Zepto is working to equip ERs and ambulances with highly-sensitive Troponin assays, accelerating myocardial injury detection. Meanwhile, Zepto’s portable Liquid Biopsy Platform can detect 1% cancer gene mutation (eg. PIK3CA, EGFR, KRAS) and achieve unparalleled specificity of 99.9%+ in less than 2 hours. This can revolutionize the $6B tissue-based biopsy market. Zepto seeks $30M, primarily to launch the Immunoassay Platform with D-Dimer assays and complete PIK3CA-focused product development on the Liquid Biopsy Platform.

Second Place: BOYDSense

BOYDSense, Inc. is a medical technology company providing non-invasive and affordable tools for measuring critical biomarkers via exhaled breath. Breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using them to diagnose and monitor chronic diseases, such as diabetes. BOYDSense’s first commercial product, the g-Sense Breath Meter, is a hand-held breath meter that can accurately predict blood glucose values from breath VOC’s. The g-Sense meter does not need consumables, is wirelessly enabled, has a companion mobile application and a public API. The device design is lifestyle-friendly, pocket-sized, with a seamless user experience, allowing consumers to frequently measure blood glucose without the typical barriers of cost, pain, or social stigma.

Third Place: Resmetrix Medical

Respiratory diseases are leading causes of death and disability in the world. More than 250 million people suffer from Chronic Obstructive Pulmonary disease (COPD) and 300 million from Asthma worldwide. Currently, respiratory deterioration is often detected too late, leading to sever exacerbation and complications, hospitalization and huge costs. Resmetrix is developing a wearable system (based on unique proprietary sensor built into a chest strap wirelessly connected to a smartphone app), that monitors at-risk respiratory patients in real-time, 24/7, anywhere, in any setting. Resmetrix system is the only system that detects small changes in a patient’s breathing pattern and provides immediate, early warning signs of deterioration in COPD patients at home, enable early window of intervention, early treatment and avoiding hospitalization.